surpass trial tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 SURPASS-2: Tirzepatide bests semaglutide in

Monitoring patient progress and side effects The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) guidelines recommend that patients receiving treatments for obesity be evaluated every 4-12 weeks

Seetharaman S, et al

Going off Zepbound will end its benefits

Your doctor might determine that a lower dose could still be effective for your primary condition while having less of an impact on your sleep (but do be careful for non-linear dosage effects)

Your Restoration MedSpa provider is dedicated to providing the information you need to make the most informed decisions about your well-being

Mast cells can also synthesize and release prostaglandin D2 and leukotrienes quickly